Another productive two weeks for neurotech. The field is still very much developing, and we saw plenty of updates that may not steal the headlines but do indicate real progress. Trial results, regulatory updates, financial wins (and losses), they all deserve a closer look. We are happy to take that look for you!But we also saw some bigger headlines. Phantom Neuro implanted its first patient with its limb interface, a technology that could change the lives of millions of upper-limb amputees. And two neurotech firms received investments from AI companies. We discuss those developments, and the broader AI x Neurotech trend, below!
.jpeg)
CorTec reported more than four years of stable recordings from its surface electrodes in two macaques at Weill Cornell Medicine. In one animal, 63 of 64 contacts still deliver usable signals more than 1,300 days after implantation. The electrodes sit on the dura without penetrating brain tissue and form the basis of CorTec's Brain Interchange system, already implanted in three stroke patients. The findings follow Paradromics' four-year sheep data in our last edition, adding to growing evidence on the durability of long-term neural implants.
.jpeg)
Paradromics received FDA approval to recruit nationwide for its Connect-One feasibility study, removing the requirement to live within four hours of a clinical site. Eligible participants from across the US can now travel to one of the three US sites. A week before, the company announced a collaboration with Siemens Healthineers to develop an integrated imaging workflow for BCI patients, from surgical planning to implant placement.
PRECISIS partnered with Odin Healthcare to introduce EASEE, its minimally invasive brain stimulation implant for drug-resistant focal epilepsy, in the Gulf states, starting with the UAE.
BrainsWay reported that more than 118 million Americans now have insurance coverage for its Deep TMS treatment for OCD. Earlier this month, coverage for its accelerated depression protocol also surpassed 70 million people.
Ampa launched Target Lock for its portable Ampa One TMS system. The new feature uses an embedded camera and neuronavigation cap to monitor coil positioning during treatment. If the coil moves off target, stimulation automatically pauses until it is realigned.
Spiro Medical treated its first patient in PULSAR, an FDA IDE feasibility study of its implantable spinal nerve stimulation system for severe asthma. The study will enroll up to 30 patients whose asthma remains uncontrolled despite biologic therapy.
Cadence Neuroscience received FDA IDE approval for BTSEE, a 45-patient study of its biomarker-targeted stimulation therapy for drug-resistant focal epilepsy. The study will run at up to 10 US epilepsy centers.
Nyxoah presented 12-month ACCCESS data, showing a 77.2% responder rate for its Genio implant in sleep apnea patients with complete concentric collapse. The company also filed with the FDA to expand its US label. Days later, it lowered its 2026 revenue guidance to €33M-€35M, citing a slower-than-expected US rollout.
Salvia BioElectronics treated its first US patient in RECLAIM-II, a pivotal randomized, double-blind trial of its MySalvia system for resistant migraine. The system uses two ultra-thin implants placed beneath the skin at the front and back of the head, activated twice daily using a wearable device. The study aims to enroll around 150 patients across more than 20 US sites.
CereGate closed an oversubscribed Series C led by an unnamed global US medtech company. The Munich-based company develops software that delivers personalized stimulation through existing deep brain stimulation implants, initially targeting freezing of gait in Parkinson's disease. Its software runs on Boston Scientific systems and has been tested in more than 85 participants. The funding amount was not disclosed.
Saluda Medical recalled certain Evoke closed-loop spinal cord stimulators after a manufacturing change caused unintended stimulation during charging or prevented charging altogether. Around 3,900 implanted devices may be affected, with 26 complaints reported. Shares fell to a record low of A$0.275. Saluda says the issue has been fixed and is working with the FDA to screen affected devices, with no expected supply disruption.
Coherence Neuro raised a $45M Series A co-led by Founders Fund and the OpenAI Startup Fund. The company develops brain implants for glioblastoma, starting with CIPHER, a thin-film cortical probe first tested in three patients this summer. The funding will support its first long-term human trial, an FDA Breakthrough Device designation application, and preclinical research in pancreatic cancer.
Zeto signed an exclusive distribution agreement with Stratus for its FDA-cleared Zeto ONE point-of-care EEG headset in US hospitals. The partnership combines Zeto's hardware with Stratus' nationwide network of EEG technologists for remote monitoring and review.
Universal Brain deployed its FDA-cleared dry-electrode EEG system at its first clinical site, Acacia Clinics in Sunnyvale, which specializes in neuromodulation for depression and other psychiatric conditions. A three-month pilot will assess how rapid brain-function measurements can fit into existing psychiatric workflows.
Beacon Biosignals acquired Snap Diagnostics, a home sleep testing provider serving patients across all 50 US states. Snap manages the entire testing process, from shipping devices to interpreting results, and bills insurers directly. Beacon says the acquisition more than doubles its patient reach and establishes a nationwide channel for EEG-enabled home sleep testing, which it plans to introduce in 2027. Financial terms were not disclosed.
Prima Mente was named one of five UK startups receiving minority investments from NVIDIA. Prima Mente develops AI models of the human epigenome for early Alzheimer's diagnosis. The investment amount was not disclosed; Prima Mente is still raising funds.
Phantom Neuro implanted its Phantom X neural interface in the first participants of its CYBORG study at Cabrini Health in Melbourne. The device sits beneath the skin over the muscles of a residual limb, detecting signals when users try to move missing fingers or a wrist and converting them into wireless commands for a prosthetic arm. The study plans to enroll 10 people with below-the-elbow amputations. Phantom, which raised a $19M Series A led by Ottobock last year, also announced plans to raise a $30M Series B.
%20copy.jpg)
.svg)
